ANNOVIS BIO (ANVS) Stock Fundamental Analysis

NYSE:ANVS • US03615A1088

2.68 USD
-0.09 (-3.25%)
At close: Feb 27, 2026
2.7 USD
+0.02 (+0.75%)
After Hours: 2/27/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ANVS. ANVS was compared to 521 industry peers in the Biotechnology industry. While ANVS seems to be doing ok healthwise, there are quite some concerns on its profitability. ANVS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ANVS had negative earnings in the past year.
  • In the past year ANVS has reported a negative cash flow from operations.
  • In the past 5 years ANVS always reported negative net income.
  • ANVS had a negative operating cash flow in each of the past 5 years.
ANVS Yearly Net Income VS EBIT VS OCF VS FCFANVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -144.77%, ANVS is doing worse than 83.11% of the companies in the same industry.
  • The Return On Equity of ANVS (-189.15%) is worse than 66.99% of its industry peers.
Industry RankSector Rank
ROA -144.77%
ROE -189.15%
ROIC N/A
ROA(3y)-265.83%
ROA(5y)-179.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANVS Yearly ROA, ROE, ROICANVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ANVS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANVS Yearly Profit, Operating, Gross MarginsANVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ANVS has been increased compared to 1 year ago.
  • The number of shares outstanding for ANVS has been increased compared to 5 years ago.
  • ANVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANVS Yearly Shares OutstandingANVS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ANVS Yearly Total Debt VS Total AssetsANVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • ANVS has an Altman-Z score of -5.80. This is a bad value and indicates that ANVS is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -5.80, ANVS is doing worse than 63.15% of the companies in the same industry.
  • There is no outstanding debt for ANVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.8
ROIC/WACCN/A
WACCN/A
ANVS Yearly LT Debt VS Equity VS FCFANVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 4.60 indicates that ANVS has no problem at all paying its short term obligations.
  • ANVS has a Current ratio of 4.60. This is comparable to the rest of the industry: ANVS outperforms 52.78% of its industry peers.
  • A Quick Ratio of 4.60 indicates that ANVS has no problem at all paying its short term obligations.
  • The Quick ratio of ANVS (4.60) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.6
Quick Ratio 4.6
ANVS Yearly Current Assets VS Current LiabilitesANVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 60.33% over the past year.
EPS 1Y (TTM)60.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ANVS will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.24% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.9%
EPS Next 2Y10.31%
EPS Next 3Y9.12%
EPS Next 5Y12.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANVS Yearly Revenue VS EstimatesANVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ANVS Yearly EPS VS EstimatesANVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ANVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ANVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANVS Price Earnings VS Forward Price EarningsANVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANVS Per share dataANVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.31%
EPS Next 3Y9.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ANVS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ANNOVIS BIO

NYSE:ANVS (2/27/2026, 8:04:00 PM)

After market: 2.7 +0.02 (+0.75%)

2.68

-0.09 (-3.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-19
Inst Owners11.46%
Inst Owner Change69.51%
Ins Owners15.56%
Ins Owner Change4.31%
Market Cap71.02M
Revenue(TTM)N/A
Net Income(TTM)-24.88M
Analysts82
Price Target14.03 (423.51%)
Short Float %13.1%
Short Ratio5.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.56%
Min EPS beat(2)-18.93%
Max EPS beat(2)22.06%
EPS beat(4)2
Avg EPS beat(4)-3.11%
Min EPS beat(4)-27.55%
Max EPS beat(4)22.06%
EPS beat(8)4
Avg EPS beat(8)-2.96%
EPS beat(12)6
Avg EPS beat(12)-20.57%
EPS beat(16)7
Avg EPS beat(16)-32.21%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.47%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.4
P/tB 5.4
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.43
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -144.77%
ROE -189.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-265.83%
ROA(5y)-179.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.6
Quick Ratio 4.6
Altman-Z -5.8
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.86%
EPS Next Y24.9%
EPS Next 2Y10.31%
EPS Next 3Y9.12%
EPS Next 5Y12.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.05%
EBIT Next 3Y-44.37%
EBIT Next 5Y-5.41%
FCF growth 1Y26.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.99%
OCF growth 3YN/A
OCF growth 5YN/A

ANNOVIS BIO / ANVS FAQ

Can you provide the ChartMill fundamental rating for ANNOVIS BIO?

ChartMill assigns a fundamental rating of 2 / 10 to ANVS.


What is the valuation status of ANNOVIS BIO (ANVS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ANNOVIS BIO (ANVS). This can be considered as Overvalued.


What is the profitability of ANVS stock?

ANNOVIS BIO (ANVS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ANNOVIS BIO?

The Earnings per Share (EPS) of ANNOVIS BIO (ANVS) is expected to grow by 24.9% in the next year.